Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
Status:
Terminated
Trial end date:
2020-09-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand the effect that T helper 2 (Th2) blockade has on
well-described pathophysiological features of Atopic Dermatitis (AD), for example: barrier,
epidermal activation, dysbiosis and epidermal lipids.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Atopic Dermatitis Research Network Regeneron Pharmaceuticals Rho Federal Systems Division, Inc. Sanofi